Year: 2022

CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr. Ulf Jungnelius M.D. and Isofol’s Board of Directors have agreed that Ulf will step down as CEO of Isofol on June 1, 2023. Isofol’s Board of Directors will take a decision regarding a new CEO once the company’s future has been determined.

Final data from the AGENT study confirms topline results

GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Moreover, no predictive gene expressions for clinical response could be identified. Isofol is continuing its efforts to terminate the AGENT study in line with applicable ethical and regulatory requirements, complete the final study report for submission to regulatory agencies and prepare a manuscript for a scientific publication. Isofol is in parallel continuing to investigate possible future paths forward for the company.

Isofol reports data from the AGENT study

GOTHENBURG, Sweden, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported data from the AGENT study that formed the basis for its assessment that it was not justified to continue the study. Isofol will continue to collect and review data related to, among other areas, subgroups and gene expression, in order to identify possible commercial value. Data has so far failed to show any concrete results of value, which means severely limited commercial potential. The AGENT study will be terminated in accordance with applicable ethical considerations and regulatory requirements, which will occur during the autumn. Parallel to this, Isofol’s Board of Directors will evaluate possible courses of action to secure the greatest possible value for Isofol’s shareholders.

Isofol provides update on the AGENT study

GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to additional data, the company does not consider it justified to continue conducting the AGENT study. Review of study data will continue until the company can compile the final study report which is estimated to take place during the fourth quarter of 2022. At the same time, Isofol’s board of directors has decided to evaluate possible courses of action for the company’s future in order to maximize its value.

Scroll to Top